Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005

Appendix 4. Changes to the Australian Standard Vaccination Schedule (1992–2005)

Disclaimer: This is the fourth report on vaccine preventable disease and vaccination coverage in Australia, and is produced by the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases and the Australian Institute of Health and Welfare on behalf of the Australian Government Department of Health and Ageing published as a supplement to the Communicable Diseases Intelligence journal Volume 31, June 2007.

Page last updated: 20 July 2007

Table 33. Diphtheria, tetanus and pertussis vaccination practice in Australia, 1992 to 2005

Date
Intervention
1994 Fifth dose of DTP at 4–5 years of age added to the recommended vaccination schedule (replacing CDT vaccine)

Active ADT school vaccination programs commenced in some states for 15–19 year olds

1996 Diphtheria-tetanus-acellular pertussis vaccine (DTPa) licensed in Australia
1997 DTPa recommended for fourth and fifth doses of DTP vaccination (due at 18 months and 4–5 years of age)
1999 DTPa recommended for all five childhood DTP doses

Combined DTPa-hepatitis B vaccine approved

2000 Second booster dose of DTPa recommended at 4 years of age instead of 4–5 years

NHMRC recommended 10 yearly booster doses of ADT be replaced with a routine booster dose at 50 years of age unless a booster dose has been documented within last 10 years

DTPa-hepB vaccine included on childhood schedule (used in Qld, NSW, ACT, SA, and NT)

Adult/adolescent formulation (dTpa) available for boosting adolescents and adults against pertussis

2001 Combined DTPa-hepB-IPV and DTPa-hepB-IPV-Hib vaccines approved
2002 Combined DTPa-IPV and DTPa-IPV-Hib vaccines approved
2003 September: Fourth dose of DTPa at 18 months of age no longer recommended. dTpa recommended at 15 years of age, replacing dT.
2004 dTpa funded at 15–17 years of age replacing the diphtheria-tetanus dose

Table 34. Haemophilus influenzae type b vaccination practice in Australia, 1992 to 2005

Date
Intervention
1992 First Hib vaccines (PRP-D, ProHIBit) licensed in Australia for vaccinating infants aged at least 18 months
1993 Hib vaccine recommended as part of the childhood vaccination schedule

Hib vaccines: HBOC (HibTITER), PRP-T (Act-HIB), and PRP-OMP (PedvaxHIB) licensed for infants aged <18 months

PRP-OMP recommended at 2, 4 and 12 months of age for Aboriginal and Torres Strait Islander children and all children in the Northern Territory, HBOC used otherwise

2000 Combined Hib(PRP-OMP)-hepatitis B vaccine approved

PRP-OMP recommended for all infants (administered separately or in combination with hepatitis B vaccine)

2001 Combined DTPa-hepB-IPV-Hib vaccine approved
2002 Combined DTPa-IPV-Hib vaccines approved
2005 November: Combined DTPa-IPV-Hib (PRP-T) vaccines used in NSW, ACT, WA and Tasmania; PRP-OMP vaccine continues to be used in other jurisdictions

Table 35. Hepatitis A vaccination practice in Australia, 1992 to 2005

Date
Intervention
1994 Hepatitis A vaccine (formaldehyde inactivated HAV) approved in Australia for at-risk groups, three doses recommended
2005 Hepatitis A vaccination (two doses recommended) recommended for Aboriginal and Torres Strait Islander children aged 12–24 months of age residing in the Northern Territory, Qld, WA and SA.

Table 36. Hepatitis B vaccination practice in Australia, 1992 to 2005

Date
Intervention
1997 Vaccination recommended for adolescents aged 10–16 years
1997 Interim recommendation for universal vaccination of infants at birth
1998 School-based programs commenced for 10–16 year olds in Victoria. A ‘catch-up’ campaign was conducted in the Northern Territory for children 6–16 years of age.
1999 SA commenced year 8 immunisation program provided by councils
  Combined DTPa-hepatitis B vaccine approved
2000 Thiomersal-free paediatric hepatitis B vaccine approved

Combined Hib(PRP-OMP)-hep B vaccine approved

May: Universal infant vaccination included in childhood schedule with a birth dose of monovalent paediatric hepatitis B vaccine, followed by three doses as part of a combination vaccine schedule

DTPa-hepB vaccine included on childhood schedule (used in Qld, NSW, ACT, SA, and NT)

Hib(PRP-OMP)-hepB vaccine included on childhood schedule (used in Tas, Vic, WA)

Preadolescent vaccination recommended at 10–13 years of age rather than 10–16 years of age

Booster doses no longer recommended by NHMRC

2001 Combined DTPa-hepB-IPV and DTPa-hepB-IPV-Hib vaccines approved

Table 37. Influenza vaccination practice in Australia, 1992 to 2005

Date
Intervention
1997 In Victoria, influenza vaccine funded for all adults aged 65 years and over
1999 Funding provided for both the national Older Australian Flu program and the National Indigenous Pneumococcal and Influenza lmmunisation (NIPII) program

Table 38. Measles, mumps and rubella vaccination practice in Australia, 1992 to 2005

Date
Intervention
1992 November: NHMRC recommended second dose of MMR vaccine for both sexes to replace schoolgirl rubella vaccination program
1993 November: Childhood vaccination schedule updated to include second dose of MMR vaccine for 10–16 year olds (replacing schoolgirl rubella vaccination)
1998 Recommended age for first dose of MMR vaccine for Aboriginal and Torres Strait Islander children in the Northern Territory increased to 12 months of age (in line with non-Aboriginal infants)

July: Recommended age for second MMR vaccine dose lowered to 4–5 years

July–December: Implementation of Measles Control Campaign (involving mass vaccination of primary school aged children with MMR vaccine)

2000 Recommended age for second MMR dose lowered to 4 years of age not 4–5 years

MMR rather than rubella vaccine recommended for non-immune women of child-bearing age

2001 Young adult (18 – 30 years) MMR vaccination campaign conducted

Table 39. Meningococcal C vaccination practice in Australia, 1992 to 2005

Date
Intervention
2001 Meningococcal C conjugate vaccine (Meningitec) approved
2002 Meningococcal C conjugate vaccines (NeisVac-C, Menjugate) approved

Funding announced for National Meningococcal C Vaccination Program commencing January 2003 with

meningococcal C conjugate vaccine (MenCCV) funded for all children 1–18 years of age, at 12 months of age with a catch-up program for older ages

2003 NHMRC endorses recommended changes. Meningococcal C conjugate vaccine added to childhood vaccination schedule at 12 months of age. National Meningococcal C Vaccination Program commences January 2003.

Table 40. Pneumococcal vaccination practice in Australia, 1992 to 2005

Date
Intervention
1994 Vaccination recommended for Aboriginal and Torres Strait Islanders living in high-risk communities aged over 50 years
1997 Vaccination recommended for all persons aged over 65 years

Vaccination recommended for all Aboriginal and Torres Strait Islanders aged over 50 years

1998 In Victoria, pneumococcal vaccine funded for all adults aged 65 years and over and all Aboriginal and Torres Strait Islanders aged 50 years and over
1999 Vaccination recommended for Aboriginal and Torres Strait Islanders aged 15–50 years with any of the high-risk underlying conditions

23-valent polysaccharide vaccine funded by the Commonwealth (under the National Indigenous Pneumococcal and Influenza Immunisation program - NIPII) for all Aboriginal and Torres Strait Islanders aged at least 50 years and those aged 15–50 years with any of the high-risk underlying conditions

2000 Vaccination recommendation for Aboriginal and Torres Strait Islanders changed from >50 to ³50 years

Vaccination recommendation for all persons changed from >65 to ³65 years

NT recommended 23-valent vaccine for all Aboriginal and Torres Strait Islander people 15 years and over

7-valent conjugate pneumococcal vaccine licensed in Australia

2001 Funding made available for the at-risk conjugate pneumococcal vaccination program (all Aboriginal and Torres Strait Islander infants; all Australian children with underlying predisposing medical conditions; non-Indigenous children residing in central Australia up to the second birthday, as catch-up vaccination)
2003 7-valent conjugate pneumococcal vaccine recommended at 2, 4 and 6 months of age
2005 January: Universal funded 7-valent pneumococcal conjugate vaccine (7vPCV) replaced the previous targeted childhood program

Universal 23-valent pneumococcal polysaccharide vaccine (23vPPV) for adults over 65 years replaced previous subsidy through the PBS

Table 41. Polio vaccination practice in Australia, 1992 to 2005

Date
Intervention
1994 Recommendation for reinforcing dose of OPV to 15 year old adolescents
2001 Combined DTPa-hepB-IPV and DTPa-hepB-IPV-Hib vaccines approved
2002 Combined DTPa-IPV and DTPa-IPV-Hib vaccines approved

Fifth dose of OPV at 15–17 years of age no longer recommended

2003 IPV recommended to replace OPV at 2, 4 and 6 months and at 4 years of age
2005 November: IPV funded to replace OPV, in combination vaccines

Table 42. Varicella vaccination practice in Australia, 1992 to 2005

Date
Intervention
2003 Varicella vaccine recommended at 18 months of age
2005 Universal funded immunisation against varicella at 18 months of age from November 2005 with a school-based catch-up program for children at 10–12 years of age not previously vaccinated and without a history of varicella infection

No funded catch-up for children 2–10 years of age

 

* See also Gidding HF, Burgess MA, Kempe AE. A brief history of vaccination and childhood vaccination practices in Australia. Med J Aust. 2001;174:37–40.

Detailed historical tables available from: www.ncirs.usyd.edu.au/publ/publ-79-tbls.html

Document download

This publication is available as a downloadable document.

Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005(PDF 1622 KB)